| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10617695 | ALLERGAN | Ophthalmic compositions containing alcaftadine |
Mar, 2027
(3 years from now) | |
| US8664215 | ALLERGAN | Ocular allergy treatments with alcaftadine |
Dec, 2027
(4 years from now) | |
Lastacaft is owned by Allergan.
Lastacaft contains Alcaftadine.
Lastacaft has a total of 2 drug patents out of which 0 drug patents have expired.
Lastacaft was authorised for market use on 28 July, 2010.
Lastacaft is available in solution/drops;ophthalmic dosage forms.
Lastacaft can be used as use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander.
The generics of Lastacaft are possible to be released after 23 December, 2027.
Drugs and Companies using ALCAFTADINE ingredient
Market Authorisation Date: 28 July, 2010
Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Dosage: SOLUTION/DROPS;OPHTHALMIC
LASTACAFT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic